Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

@article{Baas1998CatecholOmethyltransferaseIW,
  title={Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.},
  author={H. Baas and Antonie Gi{\ae}ver Beiske and Joseph A. Ghika and Mark Jackson and Wolfgang Hermann Oertel and Werner Poewe and Gerhard Ransmayr},
  journal={Neurology},
  year={1998},
  volume={50 5 Suppl 5},
  pages={S46-53}
}
BACKGROUND More than 50% of patients with Parkinson's disease develop motor response fluctuations (the 'wearing off" phenomenon) after more than five years of levodopa therapy. Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa. OBJECTIVES The primary objective was to evaluate the efficacy of tolcapone in reducing "wearing off" in levodopa treated, fluctuating… CONTINUE READING